# Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients

> **NCT01599754** · PHASE3 · TERMINATED · sponsor: **SFJ Pharma Ltd. II** · enrollment: 724 (actual)

## Conditions studied

- Clear Cell Renal Carcinoma

## Interventions

- **DRUG:** Axitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01599754
- **Lead sponsor:** SFJ Pharma Ltd. II
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04
- **Primary completion:** 2017-10-10
- **Final completion:** 2018-05
- **Target enrollment:** 724 (ACTUAL)
- **Why stopped:** Primary endpoint did not reach statistical significance
- **Last updated:** 2019-09-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01599754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01599754, "Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01599754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*